Abstract: A construction machine is provided. The construction machine includes a chassis and a ground engaging member (such as a wheel or a track) operable to support and move the chassis over ground. The construction machine further includes a work implement (such as a bucket) coupled to the chassis; a cab mounted on said chassis and having a user seat, and a first controller (such as a joystick) accessible to a user seated in the user seat. The joystick controls at least one of moving the work machine over ground and movement of the bucket. The joystick has a first actuator (such as a trigger button) that is operable to selectively engage ride control functionality.

Abstract: A construction machine is provided. The construction machine includes a chassis and a ground engaging member (such as a wheel or a track) operable to support and move the chassis over ground. The construction machine further includes a work implement (such as a bucket) coupled to the chassis; a cab mounted on said chassis and having a user seat, and a first controller (such as a joystick) accessible to a user seated in the user seat. The joystick controls at least one of moving the work machine over ground and movement of the bucket. The joystick has a first actuator (such as a trigger button) that is operable to selectively engage ride control functionality.

Abstract: Described is a method of identifying antibodies against hitherto unknown ligands of orphan receptors or other orphan ligands, i.e., receptors or other ligands where the counter-ligand has not yet been identified. The availability of antibodies binding to the unknown ligand significantly facilitates their isolation and characterization, and the identified antibodies can themselves be useful for treating patients with cancer or autoimmune diseases, or other disorders. An exemplary embodiment provides for a method designated Identification of Therapeutic Antibodies by Competitive Screening (ITACS). Described are also fusion proteins comprising a soluble portion of an orphan receptor, such as NKp30, and the Fc portion of an antibody. The fusion proteins typically comprise a Flexible Transmembrane Linker (FTL), i.e., a linker comprising a portion of a transmembrane domain of the orphan receptor.